Abstract
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
Original language | English (US) |
---|---|
Pages (from-to) | 243-249 |
Number of pages | 7 |
Journal | Clinical, Cosmetic and Investigational Dermatology |
Volume | 7 |
DOIs | |
State | Published - Sep 2 2014 |
Keywords
- Psoriasis
- Psoriatic arthritis
- Ustekinumab
ASJC Scopus subject areas
- Dermatology